Clarentis Technologies LLC disrupts clinical sanitation frameworks through fully automated Onsite Generation (OSG) of Ultra-Lyte® hypochlorous acid (HOCl). Validated under EPA Reg. No. 86854-1 as a medical hospital disinfectant, our point-of-use synthesis provides legacy chemical distributors with a legally cleared, high-efficacy alternative to traditional quats and phenols.
- Federal EPA Registration: Officially registered as an EPA Medical & Hospital Disinfectant (86854-1), with authorized efficacy claims against critical healthcare pathogens including Clostridioides difficile (C. diff) and Candida auris.
- 3 ppm Biofilm Eradication: Peer-reviewed and published in the Journal of Hospital Infection (accessible under our website's IP & Technology Platform); continuous dosing of just 3 ppm Ultra-Lyte completely removes established biofilm matrices from hospital water lines.
- Sporicidal Efficacy Baseline: Rapidly eradicates stubborn clinical pathogens, drug-resistant superbugs, and dangerous viral loads without causing surface material degradation or cleanroom asset pitting.
- Zero-PPE Profile & Category 4 Rating: Classified as a Category 4 low-toxicity biocide requiring zero specialized PPE for application, significantly minimizing workplace safety liabilities compared to toxic legacy fluids.
- Scope 3 Emission Reductions: Enhances healthcare enterprise ESG ratings by bypassing traditional plastic drum freight loops and eliminating toxic effluent footprints in local municipal wastewater.